Shares of Kadmon Holdings Inc (NASDAQ:KDMN) soared 20.56% or 75 cents to $4.28 per share on heavy volume after the company has announced that FDA has approved REZUROCK™ (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of...
A close above 5.50 gets things going
$KDMN is set up well both technically and fundamentally. The FDA just approved CLOVIQUE (TM), A Room-Temperature Stable Trientine Hydrochloride Product. This bodes well for the company as it moves forward. According to the press release: Product Offers Room Temperature Stability, Improving Convenience for Patients NEW YORK, NY / ACCESSWIRE / October 21, 2019 /...
KDMN is breaking of a falling wedge & seems like a perfect fallen angel pattern. Both suggesting a strong upward move. * Trade Criteria * Date first found- Pattern/Why- Entry Target Criteria- Break of 4.09 or pullback to 3.80 Exit Target Criteria- $5.43/6.22 Stop Loss Criteria- $3.67 Please check back for Trade updates. (Note: Trade update is little...